Form Approved OMB No. 0920-0666 Exp. Date: 06/30/2026 www.cdc.gov/nhsn



Glycemic Control Module—Annual Hospital Survey

Instr	ructions for this form are available	at:				
Page	1 of 2					
*required for saving			Tracking #:			
Facil	ity ID:					
Sect	ion 1. Facility Characteristics					
1.	Ownership (check one):					
	For profit	☐ Not for profit, including church		☐ Government		
	Military	\square Veterans Aff	airs	\square Physician owned		
If for	sility is a Hospital.					
	cility is a Hospital: nber of patient days:					
	nber of admissions:					
ivai	mber of duffissions					
For a	any Hospital:					
2. Is	your hospital a teaching hospital for p	hysicians and/or physic	cians-in-training?			
If Y	'es, what type:	\square Major	\square Graduate	\Box Undergraduate		
3. N	umber of beds set up and staffed in th	e following location type	es (as defined by NHSN):			
	CU (including adult, pediatric, and ned		,			
	All other inpatient locations:		7			
	ion 2. Glycemic Control Program					
3. D	oes your facility have an inpatient g	ylycemic control quali	ty improvement or safety progr	am in place as demonstrated		
	□ Special team(s) dedicated to consulting on patients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively assist in the management of inpatients with diabetes that actively actively actively active					
be use	nnce of Confidentiality: The voluntarily provided infectionly for the purposes stated, and will not otherwand 242m(d)).			•		
compl comm	reporting burden of this collection of information is eting and reviewing the collection of information. A ents regarding this burden estimate or any other as 0666).	An agency may not conduct or s	ponsor, and a person is not required to respo	nd to a collection of information unless it d		
CDC (<mark>f</mark>	orm number) Rev (Add release and release date)					
	□ Staff from key support departments and groups who contribute to glycemic control activities □ At least annual presentation of information on glycemic control activities and outcomes to facility leadership and/or board □ At least annual opportunity to address glycemic control resource needs with facility leadership and/or board □ Facility communication mechanisms about glycemic control activities, via email, newsletters, events, or other avenues □ Provision of facility staff training and development on glycemic control activities □ Documented statement of facility support for glycemic control activities (e.g., a written policy or statement approved by the					

☐ Our facility does not have a glycemic control quality improvement or safety program in place

Form Approved OMB No. 0920-0666 Exp. Date: 06/30/2026 www.cdc.gov/nhsn



□ Our facility has other glycemic control programmatic components, please describe briefly: _____

Se	Section 3. Glycemic Control Practices*					
4.	Does your facility have inpatient glycemic control quality improvement or safety practices as demonstrated by: (Chec					
	 □ Provider education □ Provider reminder systems □ Active surveillance for glucose control metrics, such as hypoglycemia/hyperglycemia events or other facilitated relay of clir □ Audit and feedback on performance to providers □ Incentives, regulation, or policy that are provider- or health system-directed □ Insulin orders/protocols that are standardized across units or the facility □ Our facility does not have practices specific to glycemic control quality improvement or patient safety □ Our facility has other glycemic control practices, please describe briefly: 					
Se	ection 4. Insulin and Hypoglycemia/Hyperglycemia Management Practices**					
5.	Describe the current state of hypoglycemia management / prevention protocols at your facility: (Check one.)					
	 □ Nurse driven protocols for hypoglycemia management / prevention are not available at our facility □ Standardized nurse driven protocols for hypoglycemia management / prevention are available, but use of the protocols are □ Standardized nurse driven protocols for hypoglycemia management / prevention are available and use of the protocols are 					
6.	Describe the level of coordination between point of care glucose testing, insulin delivery, and nutrition delivery on the (Check one.)					
	☐ There is not a systematic mechanism or protocol to coordinate glucose testing, insulin administration, and meal/nutrition sched ☐ There is a systematic mechanism or protocol to coordinate glucose testing, insulin administration, and meal/nutrition sched ☐ There is a systematic mechanism or protocol to coordinate glucose testing, insulin administration, and meal/nutrition sched					
7.	Select the description that most accurately reflects the approach to glycemic control and insulin management in the n (Check one.)					
	 □ No protocol is available in the non-critical care units at our facility □ Our facility has a protocol for insulin and hyperglycemia management (including subcutaneous insulin orders) that outlines situations; however, the protocol guidance is not embedded in order sets □ Our facility has a protocol for insulin management and hyperglycemia (including, subcutaneous insulin orders) that is integrated providers must "opt in" □ Our facility has an institutionally-endorsed protocol for insulin and hyperglycemia management (including, subcutaneous in standardized order sets and that require providers to "opt out" □ Our facility has an institutionally-endorsed protocol for insulin and hyperglycemia management (including, subcutaneous in standardized order sets that require the provider to "opt out" and hyperglycemia/ hypoglycemia are monitored on a regular in insulin / diabetes management □ Protocol-driven insulin management and hyperglycemia protocols are reinforced by other methods at our facility. Please breaches 					
Section 5. Glycemic Control Software Tools & Additional Information						
	Does your facility have an EHR-based glycemic control ("glucometrics") software or tool to support a glycemic control one.) Yes If yes, what is the name of the software / tool: No Unsure					
9.	Approximately what percentage of your inpatient population with diabetes is utilizing continuous glucose monitoring (





-					
□%					
☐ Unsure					
*Adapted from Society for Hospital Medicine. The Glycemic Control Implementation Guide. 2 nd ed. Ed. Maynard G, Berg K,					
Kulasa K, O'Malley C, Rogers KM. Available at: https://www.hospitalmedicine.org/globalassets/clinical-topics/clinical-pdf/gcmi-					
guide-m4.pdf.					
**Adapted from the University of California, San Diego Center for Innovation and Improvement Science, with permission from					
Greg Maynard, MD, MSc					